JP6796737B1 - 多項目自動血球計数装置 - Google Patents
多項目自動血球計数装置 Download PDFInfo
- Publication number
- JP6796737B1 JP6796737B1 JP2020095973A JP2020095973A JP6796737B1 JP 6796737 B1 JP6796737 B1 JP 6796737B1 JP 2020095973 A JP2020095973 A JP 2020095973A JP 2020095973 A JP2020095973 A JP 2020095973A JP 6796737 B1 JP6796737 B1 JP 6796737B1
- Authority
- JP
- Japan
- Prior art keywords
- cells
- immune
- information
- unit
- immunodynamic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000601 blood cell Anatomy 0.000 title claims description 43
- 210000002865 immune cell Anatomy 0.000 claims abstract description 107
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 88
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 71
- 238000004458 analytical method Methods 0.000 claims abstract description 62
- 239000000427 antigen Substances 0.000 claims abstract description 58
- 108091007433 antigens Proteins 0.000 claims abstract description 58
- 102000036639 antigens Human genes 0.000 claims abstract description 58
- 238000004820 blood count Methods 0.000 claims abstract description 55
- 238000001514 detection method Methods 0.000 claims abstract description 54
- 230000008859 change Effects 0.000 claims abstract description 43
- 238000012360 testing method Methods 0.000 claims abstract description 28
- 239000012503 blood component Substances 0.000 claims abstract description 9
- 210000000822 natural killer cell Anatomy 0.000 claims description 95
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 40
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 37
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 34
- 206010022000 influenza Diseases 0.000 claims description 31
- 230000036039 immunity Effects 0.000 claims description 26
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 25
- 239000000306 component Substances 0.000 claims description 23
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 claims description 22
- 108010041397 CD4 Antigens Proteins 0.000 claims description 19
- 230000024932 T cell mediated immunity Effects 0.000 claims description 17
- 210000000447 Th1 cell Anatomy 0.000 claims description 15
- 208000015181 infectious disease Diseases 0.000 claims description 14
- 210000003714 granulocyte Anatomy 0.000 claims description 13
- 230000004727 humoral immunity Effects 0.000 claims description 12
- 230000006870 function Effects 0.000 claims description 9
- 210000002751 lymph Anatomy 0.000 claims description 6
- 208000035473 Communicable disease Diseases 0.000 claims description 5
- 210000000467 autonomic pathway Anatomy 0.000 claims description 3
- 238000010224 classification analysis Methods 0.000 claims description 3
- 210000005036 nerve Anatomy 0.000 claims description 3
- 230000002889 sympathetic effect Effects 0.000 claims description 3
- 210000005037 parasympathetic nerve Anatomy 0.000 claims description 2
- 238000010586 diagram Methods 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 29
- 230000007261 regionalization Effects 0.000 description 25
- 238000004364 calculation method Methods 0.000 description 22
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 20
- 208000005718 Stomach Neoplasms Diseases 0.000 description 17
- 206010017758 gastric cancer Diseases 0.000 description 17
- 201000011549 stomach cancer Diseases 0.000 description 17
- 210000001744 T-lymphocyte Anatomy 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 210000000440 neutrophil Anatomy 0.000 description 13
- 206010039073 rheumatoid arthritis Diseases 0.000 description 13
- 206010012438 Dermatitis atopic Diseases 0.000 description 12
- 201000008937 atopic dermatitis Diseases 0.000 description 12
- 206010030154 Oesophageal candidiasis Diseases 0.000 description 11
- 201000004681 Psoriasis Diseases 0.000 description 11
- 210000001616 monocyte Anatomy 0.000 description 11
- 238000011084 recovery Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 230000009469 supplementation Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 210000005087 mononuclear cell Anatomy 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 8
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 8
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 8
- 210000003651 basophil Anatomy 0.000 description 8
- 210000003979 eosinophil Anatomy 0.000 description 8
- 108010003639 CD56 Antigen Proteins 0.000 description 7
- 102000004652 CD56 Antigen Human genes 0.000 description 7
- 210000000068 Th17 cell Anatomy 0.000 description 6
- 210000004241 Th2 cell Anatomy 0.000 description 6
- 208000036142 Viral infection Diseases 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 210000004970 cd4 cell Anatomy 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000015788 innate immune response Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 4
- 235000019621 digestibility Nutrition 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000001447 compensatory effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000000222 eosinocyte Anatomy 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 238000012123 point-of-care testing Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 231100001039 immunological change Toxicity 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
- G01N15/1459—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/30—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration
- C12M41/36—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration of biomass, e.g. colony counters or by turbidity measurements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/1031—Investigating individual particles by measuring electrical or magnetic effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1429—Signal processing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1429—Signal processing
- G01N15/1433—Signal processing using image recognition
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1468—Optical investigation techniques, e.g. flow cytometry with spatial resolution of the texture or inner structure of the particle
- G01N15/147—Optical investigation techniques, e.g. flow cytometry with spatial resolution of the texture or inner structure of the particle the analysis being performed on a sample stream
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/00584—Control arrangements for automatic analysers
- G01N35/00722—Communications; Identification
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
- G01N2015/016—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1006—Investigating individual particles for cytology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1024—Counting particles by non-optical means
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N2015/1477—Multiparameters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N2015/1486—Counting the particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/00584—Control arrangements for automatic analysers
- G01N35/00722—Communications; Identification
- G01N2035/00891—Displaying information to the operator
- G01N2035/0091—GUI [graphical user interfaces]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Signal Processing (AREA)
- Virology (AREA)
- Ecology (AREA)
- Sustainable Development (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Physiology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Computer Vision & Pattern Recognition (AREA)
Abstract
Description
図1に示したように、第1実施形態の多項目自動血球計数装置1は、基礎情報生成部2、免疫細胞亜群検出部3、免疫動態変化解析部4、記憶部5及び表示部6を備える。
免疫細胞基礎データは、少なくとも、白血球数と、白血球中の好塩基球と、好酸球と、好中球と、リンパ球と、単球と、CD3抗原と、CD56抗原(および/またはCD16抗原)と、CD4抗原ならびにCD8抗原などの数量及び割合を含む。
第一の工程では、被検者から血液を採集し、基礎情報生成部2が血液を分析して、白血球数、白血球中の好塩基球の割合(%)、好酸球の割合(%)、好中球の割合(%)、リンパ球の割合(%)、単球の割合(%)に関わる情報及びCD3抗原、CD56抗原(および/またはCD16抗原)、CD4抗原ならびにCD8抗原に関わるCD分類の解析情報を取得し、記憶部5に保存する。
(数式1)
(数式2)
パターン形成例1では、インフルエンザ感染に関するパターン形成に基づいて、免疫動態変化解析部4の機能について説明する。
まず、本実施形態に係る多項目自動血球計数装置1を有する医療現場で、被検者の血液を採集し、基礎情報生成部2を用いて、当該被検者の白血球数と、白血球像(白血球分画情報)と、白血球細胞(免疫細胞)の表面抗原のCD番号の解析結果とを獲得し、記憶部5に記憶する。
まず、胃がん患者(被検者)の血液を採集し、基礎情報生成部2及び免疫細胞亜群検出部3が胃がん患者の免疫細胞基礎データを獲得する。
また、パターン形成モジュール401は、以下の免疫評価基準データA)からC)に基づいて、パターンを形成する。
A)Self−immunity Healthy −degree (自己免疫力の健康度)
・CD4 Helper−T cell 亜群(=ヘルパーT細胞免疫中枢)個数/μL/ml
・CD4 > 600/μl ⇒ normal Immunity (正常)
・CD4 600〜400 /μl ⇒Immune−decline (免疫低下)
・CD4 400〜 200/μl ⇒ Immune−impaired (免疫異常)
・CD4 < 200/μl ⇒ Immune−crisis (免疫危機)
B)体内免疫方向
・Th1細胞性免疫=NK+CD8(killer−T)
・Th2液性免疫=NKT+B cell
・CD4>CD8 >B cellの正比例(≒リンパ亜群比例パータン)
C)体内免疫自律神経バランス
・顆粒級:単核球:リンパ球 =60:5:35%(正常人の平均値)
⇒交感神経(顆粒球>リンパ球%)/副交感神経優位(リンパ球>顆粒球%)
D)体内免疫細胞群の代償変化(常に変化なので最初からのモニタリングデータを基準に)
・その他変化するバターン。
本実施例においては、上記免疫評価基準データA)からC)は、予めデータストア501(又は記憶部5)に蓄積されている。
出力例2では、Th2液性免疫優位傾向パターンに属する免疫状態を出力する一例を示す。Th2液性免疫優位傾向パターンの特徴を考慮して、被検者としては、慢性関節リウマチ患者とアトピー性皮膚炎患者を例に説明する。
出力例3において、免疫状態及び病状を正確に判断するために、他の病状パターンと比較するために、被検者の免疫状態パターンと異なる病状パターン(比較状態パターン)を同時に呈示して、比較する例について説明する。被検者の免疫細胞基礎データ41は、出力例1と同様な方法で獲得するため、その説明は省略する。
出力例4では、NK細胞低下パターンの被検者(被検者1)にNK細胞(自己培養細胞)を投与し、その免疫状態の変化(免疫動態変化)を時系列に画像化して呈示し、免疫動態モデル43を形成する。図10は、本実施形態に係る免疫動態相関部402が形成する免疫動態モデル43を示す図である。
2 基礎情報生成部
3 免疫細胞亜群検出部
4 免疫動態変化解析部
5 記憶部
6 表示部
401 パターン形成モジュール
402 免疫動態相関部
403 自己学習システム
501 データストア
Claims (8)
- 基礎情報生成部と、免疫細胞亜群検出部と、免疫動態変化解析部と、記憶部と、表示部とを備え、
前記基礎情報生成部は、血液成分の血算及び白血球像の検査情報と、リンパ球の表面抗原と結合するモノクローナル抗体のCD分類の解析情報とを獲得し、前記記憶部に記憶するように構成され、
前記免疫細胞亜群検出部は、前記血液成分の血算及び白血球像の検査情報と、前記リンパ球の表面抗原と結合するモノクローナル抗体のCD分類の解析情報とに基づいて、被検者の免疫状態の分析に必要な免疫細胞亜群の情報を検出するように構成され、
前記免疫動態変化解析部は、前記基礎情報生成部及び前記免疫細胞亜群検出部で検査された情報と前記記憶部に保存されているデータとに基づいて、少なくとも被検者の免疫動態変化に関する情報を識別し、前記表示部に画像化して呈示するように構成され、
前記免疫動態変化解析部は、免疫状態パターンを形成するパターン形成部と、前記免疫状態パターンに対して当該被検者の免疫動態相関に関する情報を呈示する免疫動態相関部と、血算のデータに応じて学習する自己学習する機能を有し、血算の各成分間の相関を特徴付ける自己学習部と、を備えることを特徴とする多項目自動血球計数装置。 - 請求項1に記載の多項目自動血球計数装置であって、
前記免疫細胞亜群検出部は、被検者の免疫状態の分析に必要な情報として、B細胞の個数、NK細胞の個数及びNKT細胞の個数を算出するとともに、少なくとも、ヘルパーT細胞の個数,キラーT細胞の個数,NK細胞の個数,NKT細胞の個数及びB細胞の個数を含む免疫リンパ細胞亜群の個数及び割合を検出することを特徴とする多項目自動血球計数装置。 - 請求項1又は請求項2に記載の多項目自動血球計数装置であって、
前記免疫細胞亜群検出部は、前記血液成分の血算及び白血球像の検査情報と、前記リンパ球の表面抗原と結合するモノクローナル抗体のCD分類の解析情報に基づいて、前記被検者の体内の免疫細胞としての白血球の総数及び免疫細胞亜群の各々の個数を検出し、
前記免疫動態変化解析部は、前記免疫細胞亜群の割合及び個数変化に基づいて免疫状態パターン又は免疫動態モデルを生成することを特徴とする多項目自動血球計数装置。 - 請求項1〜請求項3のいずれか一項に記載の多項目自動血球計数装置であって、
前記自己学習部は、前記記憶部に記憶されている全顆粒球、全リンパ、CD4抗原、CD8抗原、NK細胞、NKT細胞及びB細胞の数量に基づいて、感染症の特徴を示すパターン範囲を特定し、前記記憶部に記憶することを特徴とする多項目自動血球計数装置。 - 請求項4に記載の多項目自動血球計数装置であって、
前記パターン形成部は、前記記憶部に記憶されている感染者のCD4抗原数、CD8抗原数、NK細胞数、NKT細胞数及びB細胞数の割合を画像化し、前記表示部に呈示し、
前記記憶部に記憶されている対比インフルエンザ感染パターン標準データを用いて、前記被検者がインフルエンザに感染しているか否かを判断するための情報を前記表示部に呈示することを特徴とする多項目自動血球計数装置。 - 請求項1〜請求項5のいずれか一項に記載の多項目自動血球計数装置であって、
前記免疫動態変化解析部は、確定した前記被検者の免疫動態変化に関する情報に基づいて、当該被検者の獲得免疫について、Th1細胞性免疫及びTh2液性免疫の優位度の情報を解析することを特徴とする多項目自動血球計数装置。 - 請求項1〜請求項5のいずれか一項に記載の多項目自動血球計数装置であって、
前記免疫動態変化解析部は、確定した前記被検者の免疫動態変化に関する情報に基づいて、当該被検者の臨床状態について、免疫代償状態及び免疫非代償状態を解析することを特徴とする多項目自動血球計数装置。 - 請求項1〜請求項5のいずれか一項に記載の多項目自動血球計数装置であって、
前記免疫動態変化解析部は、確定した前記被検者の免疫動態変化に関する情報に基づいて、当該被検者の自律神経について交感神経及び副交感神経の優位度を解析することを特徴とする多項目自動血球計数装置。
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020095973A JP6796737B1 (ja) | 2020-06-02 | 2020-06-02 | 多項目自動血球計数装置 |
US16/943,483 US20210371803A1 (en) | 2020-06-02 | 2020-07-30 | Multi-parameter automatic blood cell counting device |
CA3180839A CA3180839A1 (en) | 2020-06-02 | 2021-05-28 | Multi-purpose automated blood cell counting device |
AU2021284070A AU2021284070A1 (en) | 2020-06-02 | 2021-05-28 | Multi-purpose automated blood cell counting device |
CN202180003031.0A CN113825997B (zh) | 2020-06-02 | 2021-05-28 | 多项目自动血球计数装置 |
EP21817325.0A EP4160183A4 (en) | 2020-06-02 | 2021-05-28 | VERSATILE AUTOMATED BLOOD CELL COUNTING DEVICE |
BR112022024204A BR112022024204A2 (pt) | 2020-06-02 | 2021-05-28 | Dispositivo de contagem automática de células sanguíneas de parâmetro múltiplo |
KR1020227045162A KR20230015435A (ko) | 2020-06-02 | 2021-05-28 | 다항목 자동 혈구 계수 장치 |
PCT/JP2021/020467 WO2021246334A1 (ja) | 2020-06-02 | 2021-05-28 | 多項目自動血球計数装置 |
TW110119961A TW202212825A (zh) | 2020-06-02 | 2021-06-02 | 多項目自動血球計數裝置 |
ZA2022/13476A ZA202213476B (en) | 2020-06-02 | 2022-12-13 | Multi-purpose automated blood cell counting device |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020095973A JP6796737B1 (ja) | 2020-06-02 | 2020-06-02 | 多項目自動血球計数装置 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP6796737B1 true JP6796737B1 (ja) | 2020-12-09 |
JP2021189081A JP2021189081A (ja) | 2021-12-13 |
Family
ID=73646857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020095973A Active JP6796737B1 (ja) | 2020-06-02 | 2020-06-02 | 多項目自動血球計数装置 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210371803A1 (ja) |
EP (1) | EP4160183A4 (ja) |
JP (1) | JP6796737B1 (ja) |
KR (1) | KR20230015435A (ja) |
CN (1) | CN113825997B (ja) |
AU (1) | AU2021284070A1 (ja) |
BR (1) | BR112022024204A2 (ja) |
CA (1) | CA3180839A1 (ja) |
TW (1) | TW202212825A (ja) |
WO (1) | WO2021246334A1 (ja) |
ZA (1) | ZA202213476B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113447664A (zh) * | 2021-04-22 | 2021-09-28 | 山东大学第二医院 | 一种凝血检测全自动样本处理*** |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1296622C (en) * | 1986-08-12 | 1992-03-03 | Jeffrey E. Anderson | Method and apparatus for automated assessment of the immunoregulatory status of the mononuclear leukocyte immune system |
EP2042867B1 (en) * | 2006-06-15 | 2010-09-22 | National University Corporation Tokyo Medical and Dental University | Immunity evaluation method, immunity evaluation apparatus, immunity evaluation program and data recording medium having the immunity evaluation program stored therein |
JP2008089382A (ja) | 2006-09-29 | 2008-04-17 | Nippon Koden Corp | 血球計数検査チップおよびこれを使用する血球計数検査装置 |
KR102022513B1 (ko) * | 2011-06-29 | 2019-09-19 | 셀레스티스 리미티드 | 감도가 증진된 세포 매개 면역 반응 검정법 |
JP6100867B1 (ja) * | 2015-11-06 | 2017-03-22 | 振武 曽 | 免疫状態の分析のための検査方法 |
AU2018218844A1 (en) * | 2017-02-07 | 2019-09-19 | Saitama Medical University | Immunological biomarker for predicting clinical effect of cancer immunotherapy |
JP7329840B2 (ja) * | 2017-12-26 | 2023-08-21 | 民男 山内 | 免疫動態に関する情報を提供する方法、システムおよびプログラム |
TW202012933A (zh) * | 2018-04-24 | 2020-04-01 | 美商健康堤爾股份有限公司 | 免疫健康(wellness)之標記及其使用方法 |
-
2020
- 2020-06-02 JP JP2020095973A patent/JP6796737B1/ja active Active
- 2020-07-30 US US16/943,483 patent/US20210371803A1/en active Pending
-
2021
- 2021-05-28 CN CN202180003031.0A patent/CN113825997B/zh active Active
- 2021-05-28 AU AU2021284070A patent/AU2021284070A1/en active Pending
- 2021-05-28 BR BR112022024204A patent/BR112022024204A2/pt unknown
- 2021-05-28 KR KR1020227045162A patent/KR20230015435A/ko not_active Application Discontinuation
- 2021-05-28 CA CA3180839A patent/CA3180839A1/en active Pending
- 2021-05-28 WO PCT/JP2021/020467 patent/WO2021246334A1/ja unknown
- 2021-05-28 EP EP21817325.0A patent/EP4160183A4/en active Pending
- 2021-06-02 TW TW110119961A patent/TW202212825A/zh unknown
-
2022
- 2022-12-13 ZA ZA2022/13476A patent/ZA202213476B/en unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113447664A (zh) * | 2021-04-22 | 2021-09-28 | 山东大学第二医院 | 一种凝血检测全自动样本处理*** |
CN113447664B (zh) * | 2021-04-22 | 2022-11-15 | 山东大学第二医院 | 一种凝血检测全自动样本处理*** |
Also Published As
Publication number | Publication date |
---|---|
CN113825997A (zh) | 2021-12-21 |
ZA202213476B (en) | 2024-04-24 |
CA3180839A1 (en) | 2021-12-09 |
JP2021189081A (ja) | 2021-12-13 |
US20210371803A1 (en) | 2021-12-02 |
EP4160183A1 (en) | 2023-04-05 |
KR20230015435A (ko) | 2023-01-31 |
CN113825997B (zh) | 2023-04-07 |
AU2021284070A1 (en) | 2023-02-02 |
TW202212825A (zh) | 2022-04-01 |
BR112022024204A2 (pt) | 2022-12-20 |
WO2021246334A1 (ja) | 2021-12-09 |
EP4160183A4 (en) | 2023-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hurst et al. | Comparison of the MOS short form-12 (SF12) health status questionnaire with the SF36 in patients with rheumatoid arthritis. | |
Raniszewska et al. | Clinical immunology Recurrent respiratory tract infections in children–analysis of immunological examinations | |
Bekwelem et al. | White blood cell count, C-reactive protein, and incident heart failure in the Atherosclerosis Risk in Communities (ARIC) Study | |
CN112002412A (zh) | 一种基于血常规数据推导疾病的***、设备、存储介质 | |
Milner et al. | Shortened bleeding time in acute myocardial infarction and its relation to platelet mass. | |
Finlay et al. | Designing and testing a computer-based screening system for transfusion-related acute lung injury | |
Das et al. | Reference ranges for lymphocyte subsets in adults from western India: influence of sex, age and method of enumeration | |
Maina et al. | Plasma concentrations of transforming growth factor beta 1 in non-progressive HIV-1 infection correlates with markers of disease progression | |
JP6796737B1 (ja) | 多項目自動血球計数装置 | |
McNerlan et al. | Age-related reference intervals for lymphocyte subsets in whole blood of healthy individuals | |
Hammoudi et al. | Phenotypes of patients with extensive tooth wear—a novel approach using cluster analysis | |
Faden et al. | Chemiluminescent response of neutrophils from patients with inflammatory bowel disease | |
Jabs et al. | Cytomegalovirus (CMV) blood DNA load, CMV retinitis progression, and occurrence of resistant CMV in patients with CMV retinitis | |
Ahmed et al. | Validation of The 30 Second Asthma Test™ as a measure of asthma control | |
Marshall | Misleading measurements: modeling the effects of blood pressure misclassification in a United States population | |
Hou et al. | Evaluation of lymphocyte function by IFN-γ secretion capability assay in the diagnosis of lymphoma-associated hemophagocytic syndrome | |
Pabón-Rivera et al. | The Complete Blood Count: A Practical Tool for the Pediatrician | |
Murugavel et al. | Establishment of T-lymphocyte subset reference intervals in a healthy adult population in Chennai, India | |
Abbas et al. | Assessment of haematological parameters of pulmonary tuberculosis patients with and without HIV infection attending two secondary health facilities in Jigawa State | |
Ako et al. | Immuno-hematological Profile Trends of HIV/AIDs Patients on HAART in the South west region of cameroon: retrospective medical report review for possible stratified follow-up pattern in low income settings | |
Fakher | Salivary ferritin and iron as a marker and new discriminating indices between iron deficiency anemia and thalassemia: a meta-analysis | |
Tokunaga et al. | Inclusion of family members without ME/CFS in research studies promotes discovery of biomarkers specific for ME/CFS | |
Al Obaidi et al. | R10 Predictors associated with secondary Raynaud’s phenomenon in children | |
Eldanasoury et al. | Usefulness of Eosin-5’-Maleimide (EMA) Dye for the Diagnosis of Hereditary Spherocytosis | |
Loos | Severe periodontitis may result in higher numbers of oral polymorphonuclear (oPMN) leukocytes in oral rinse samples |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200602 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20200604 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20200623 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200901 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200928 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201110 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201116 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6796737 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |